PrincipleAntihuman 尾-lipoproteins antibody in the Reagent 1 binds to lipoproteins (LDL, VLDL and chylomicrons) other then HDL. The antigen-antibody complexes formed blocked enzyme reaction when R2 is added. Cholesterol esterase (CHES) and cholesterol oxidase (CHOD) in R2 react only with HDL ...
HDL Cholesterol-Direct Clearance Method Direct Clearance Method Liquid ready-to-use reagents Stable to expiry when stored at 2-8°CCat NoSize CH2655 R1 6 x 78ml (L) R2 3 x 52ml Enquire Kit Insert Request MSDS Buy Online CH3811 R1 3 x 51ml (L) R2 3 x 20ml Enquire Kit Insert ...
Direct HDL-Cholesterol Assay Kit(D-HDL-C) Clearance Cat. 2236/2736: R1, 60ml×4 2237/2737: R2, 20ml×4 Intended Use: For the quant..
贝登医疗高密度脂蛋白胆固醇测定试剂盒Direct HDL Cholesterol医疗器械注册证主要信息:注册证编号为国械注进20152401885、注册人名称为Prodia Diagnostics。
高密度脂蛋白胆固醇测定试剂盒(直接法)Direct HDL Cholesterol Reagents (D-HDL),试剂1:两性离子(Goods)缓冲液、N‑(2-羟基-3-磺丙基)-3,5-二甲氧基苯胺、胆固醇酯酶、胆固醇氧化酶、过氧化氢酶;试剂2:两性离子(Goods) 缓冲液、4-氨基安替比林、过氧化物酶、叠氮钠。(
高密度脂蛋白胆固醇测定试剂盒(直接法)Direct HDL Cholesterol Reagents (D-HDL),试剂1: 两性离子(Goods)缓冲液、N-(2-羟基-3-磺丙基)-3,5-二甲氧基苯胺、胆固醇酯酶、胆固醇氧化酶、过氧化氢酶;试剂2:两性离子(Goods)缓冲液、4-氨基安替比林、过氧化物酶、叠氮钠。(具体
As such, the focus of HDL has now started to shift away from a cholesterol-centric view toward HDL particle number, subclasses, and other alternative metrics of HDL. Many of the recently discovered functions of HDL are, in fact, not strictly conferred by its ability to promote cholesterol ...
高密度脂蛋白胆固醇(HDL cholesterol,HDL-C)是含有ApoAⅠ、ApoAⅡ、磷脂和胆固醇的小型脂蛋白颗粒,主要功能是参与胆固醇逆转运,因而被认为具有抗动脉粥样硬化(atherosclerosis,AS)作用。血清HDL-C的测定,大致可分为超速离心法、电泳法、色谱法、沉淀法、匀相法等。《中国血脂临床检测指南》(2022版)[1]建议采用匀相法...
Dear Ann, There is a method to test direct LDL cholesterol (not calculated) but it is not very common. Once you get your heartscan and NMR LipoProfile results and if your doctor is proven to be dead wrong, then I suggest you drop him. ...
HDL-cholesterol and causes of death in chronic kidney diseaseHDL-cholesterolmortalitycardiovascularmalignancykidney diseaseIn a non-dialysis dependent CKD population, HDL-c ≤40 mg/dl was associated with risk of higher all-cause, cardiovascular, malignancy and non-cardiovascular/non-malignancy mortality ...